nach oben

High Blood Pressure & Cardiovascular Prevention

Erschienen in:

01.02.2020 | Original article

Evaluation of Serum Urocortin 2 Levels in Patients with Hypertension

verfasst von: Gamze Aslan, Saide Aytekin

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Urocortin 2 (UCN2), is an endogenous stress-related peptide belonging to the corticotropin-releasing factor (CRF) family, has a major role in the pathogenesis of congestive heart failure, ischemic heart disease, and hypertension.

Aim

To investigate the role of UCN2 levels in patients with hypertension (HTN).

Methods

Serum UCN2 levels measured by ELISA were compared between patients with HTN (n = 86) and nonHTN (n = 53).

Results

Eighty-six patients with HTN [median age 66 (45–76); 38 men] and 53 patients with non-HTN [median age 62 (40–80); 39 men] were included into this study. Serum UCN2 (5.17 ng/ml; IQR, 1.26–11.68 ng/ml vs 0.79 ng/ml; IQR, 0.07–4.10 ng/ml, p < 0.0005) levels were found significantly elevated in patients with HTN compared to nonHTN control group. Concentrations of serum UCN2 were positively correlated with left ventricle mass index to body surface area (LV mass index to BSA, r = 0.20, p = 0.03), LV mass index to height^2.7 (r = 0.28, p = 0.002) and body mass index (r = 0.24, p = 0.008). Additionally, logistic regression analysis was performed to UCN2, uric acid, creatinine, glomerular filtration rate, age, body mass index, coronary artery disease and diabetes mellitus which are the potential confounders of hypertension. According to logistic regression analysis serum UCN2 values were found out as an independent predictor of HTN.

Conclusion

UCN2 levels, correlated with LV mass index were increased in HTN patients compared to nonHTN patients. These data provide evidence that there could be a relationship between high concentrations of UCN2 and HTN. UCN2 may appear as a promising choice of HTN treatment in the future.

Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL, et al. Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA. 2008;105(10):3939–44. https://doi.org/10.1073/pnas.0712366105.CrossRefPubMed

Dermitzaki E, Tsatsanis C, Minas V, Chatzaki E, Charalampopoulos I, Venihaki M, et al. Corticotropin-releasing factor (CRF) and the urocortins differentially regulate catecholamine secretion in human and rat adrenals, in a CRF receptor type-specific manner. Endocrinology. 2007;148(4):1524–38. https://doi.org/10.1210/en.2006-0967.CrossRefPubMed

Rossant CJ, Pinnock RD, Hughes J, Hall MD, McNulty S. Corticotropin-releasing factor type 1 and type 2alpha receptors regulate phosphorylation of calcium/cyclic adenosine 3′,5′-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase. Endocrinology. 1999;140(4):1525–36. https://doi.org/10.1210/endo.140.4.6656.CrossRefPubMed

Van Kolen K, Dautzenberg FM, Verstraeten K, Royaux I, De Hoogt R, Gutknecht E, et al. Corticotropin releasing factor-induced ERK phosphorylation in AtT20 cells occurs via a cAMP-dependent mechanism requiring EPAC2. Neuropharmacology. 2010;58(1):135–44. https://doi.org/10.1016/j.neuropharm.2009.06.022.CrossRefPubMed

Yang LZ, Kockskamper J, Khan S, Suarez J, Walther S, Doleschal B, et al. cAMP- and Ca(2)(+)/calmodulin-dependent protein kinases mediate inotropic, lusitropic and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytes. Br J Pharmacol. 2011;162(2):544–56. https://doi.org/10.1111/j.1476-5381.2010.01067.x.CrossRefPubMedPubMedCentral

Grossini E, Molinari C, Mary DA, Uberti F, Ribichini F, Caimmi PP, et al. Urocortin II induces nitric oxide production through cAMP and Ca²⁺ related pathways in endothelial cells. Cell Physiol Biochem. 2009;23(1–3):87–96. https://doi.org/10.1159/000204097.CrossRefPubMed

Ikeda K, Tojo K, Otsubo C, Udagawa T, Hosoya T, Tajima N, et al. Effects of urocortin II on neonatal rat cardiac myocytes and non-myocytes. Peptides. 2005;26(12):2473–81. https://doi.org/10.1016/j.peptides.2005.05.021.CrossRefPubMed

Grossini E, Molinari C, Mary DA, Marino P, Vacca G. The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitric-oxide-dependent. Eur J Pharmacol. 2008;578(2–3):242–8. https://doi.org/10.1016/j.ejphar.2007.09.018.CrossRefPubMed

Dieterle T, Meili-Butz S, Buhler K, Morandi C, John D, Buser PT, et al. Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy? Hypertension. 2009;53(4):739–44. https://doi.org/10.1161/HYPERTENSIONAHA.108.125211.CrossRefPubMed

10.

Chen CY, Doong ML, Rivier JE, Tache Y. Intravenous urocortin II decreases blood pressure through CRF(2) receptor in rats. Regul Pept. 2003;113(1–3):125–30.CrossRef

11.

Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, et al. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci USA. 2004;101(10):3697–702. https://doi.org/10.1073/pnas.0307324101.CrossRefPubMed

12.

Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 2004;145(1):24–35. https://doi.org/10.1210/en.2003-0689(discussion 21–23).CrossRefPubMed

13.

Huang Y, Chan FL, Lau CW, Tsang SY, He GW, Chen ZY, et al. Urocortin-induced endothelium-dependent relaxation of rat coronary artery: role of nitric oxide and K + channels. Br J Pharmacol. 2002;135(6):1467–76. https://doi.org/10.1038/sj.bjp.0704587.CrossRefPubMedPubMedCentral

14.

Chen ZW, Huang Y, Yang Q, Li X, Wei W, He GW. Urocortin-induced relaxation in the human internal mammary artery. Cardiovasc Res. 2005;65(4):913–20. https://doi.org/10.1016/j.cardiores.2004.11.018.CrossRefPubMed

15.

Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation. 2005;112(23):3624–32. https://doi.org/10.1161/CIRCULATIONAHA.105.561308.CrossRefPubMed

16.

Phrommintikul A, Sivasinprasasn S, Lailerd N, Chattipakorn S, Kuanprasert S, Chattipakorn N. Plasma urocortin in acute myocardial infarction patients. Eur J Clin Invest. 2010;40(10):874–82. https://doi.org/10.1111/j.1365-2362.2010.02343.x.CrossRefPubMed

17.

Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450–8. https://doi.org/10.1016/0002-9149(86)90771-x.CrossRefPubMed

18.

Yang C, Xu Y, Li S. Urocortin: a beneficial or detrimental agent to endothelium? Biochem Biophys Res Commun. 2008;371(3):345–9. https://doi.org/10.1016/j.bbrc.2008.01.157.CrossRefPubMed

19.

Tsuda T, Takefuji M, Wettschureck N, Kotani K, Morimoto R, Okumura T, et al. Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction. J Exp Med. 2017;214(7):1877–88. https://doi.org/10.1084/jem.20161924.CrossRefPubMedPubMedCentral

20.

Liew OW, Yandle TG, Chong JP, Ng YX, Frampton CM, Ng TP, et al. High-sensitivity sandwich ELISA for plasma NT-proUcn2: plasma concentrations and relationship to mortality in heart failure. Clin Chem. 2016;62(6):856–65. https://doi.org/10.1373/clinchem.2015.252932.CrossRefPubMed

21.

Cipriano C, Gosse P, Bemurat L, Mas D, Lemetayer P, N’Tela G, et al. Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens. 2001;14(6 Pt 1):524–9. https://doi.org/10.1016/s0895-7061(01)01289-4.CrossRefPubMed

22.

Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Interactions of enhanced urocortin 2 and mineralocorticoid receptor antagonism in experimental heart failure. Circ Heart Fail. 2013;6(4):825–32. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000205.CrossRefPubMed

23.

Rademaker MT, Charles CJ, Nicholls G, Richards M. Urocortin 2 sustains haemodynamic and renal function during introduction of beta-blockade in experimental heart failure. J Hypertens. 2011;29(9):1787–95. https://doi.org/10.1097/HJH.0b013e3283493776.CrossRefPubMed

24.

Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Clin Sci (Lond). 2008;114(10):635–42. https://doi.org/10.1042/CS20070364.CrossRefPubMed

25.

Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, et al. Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol. 2007;49(4):461–71. https://doi.org/10.1016/j.jacc.2006.09.035.CrossRefPubMed

Titel: Evaluation of Serum Urocortin 2 Levels in Patients with Hypertension
verfasst von: Gamze Aslan
Saide Aytekin
Publikationsdatum: 01.02.2020
Verlag: Springer International Publishing
Erschienen in: High Blood Pressure & Cardiovascular Prevention / Ausgabe 1/2020
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI: https://doi.org/10.1007/s40292-019-00357-x

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Evaluation of Serum Urocortin 2 Levels in Patients with Hypertension

Abstract

Introduction

Aim

Methods

Results

Conclusion

Neu im Fachgebiet Kardiologie

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

ADHS-Medikation erhöht das kardiovaskuläre Risiko

LDL-Cholesterin kann ApoB als Risikomarker nicht ersetzen

Update Kardiologie

Springer Medizin

Abstract

Introduction

Aim

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Parental Perception of Children’s Weight Status: Love Overpasses Scientific Evidence! A Cross-Sectional Observational Study

Gender Differences in the Pattern of Socio-Demographics Relevant to Metabolic Syndrome Among Kenyan Adults with Central Obesity at a Mission Hospital in Nairobi, Kenya

PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease

Low Dose Resistance Exercise: A Pilot Study Examining Effects on Blood Pressure and Augmentation Index Between Intensities

Clinical Relevance of Orthostatic Hypotension in Patients with Atrial Fibrillation and Suspected Transient Ischemic Attack

From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis

Neu im Fachgebiet Kardiologie

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

ADHS-Medikation erhöht das kardiovaskuläre Risiko

LDL-Cholesterin kann ApoB als Risikomarker nicht ersetzen

Update Kardiologie